Product

Description

Triple hormone receptor agonist (GIP + GLP-1 + glucagon) Considered

the next generation after Tirzepatide with stronger weight-loss effects.

• More potent appetite suppression and fat loss than semaglutide or

tirzepatide (shown in early studies).

Note: The packaging contains an inconsistency: the dosing table lists a maximum of 12 mg in Week 8, while the administration section states a maximum of 8 mg weekly.
Dosing flexibility:
The packaging states that the weekly administration day may be adjusted if necessary, provided at least 48 hours between doses.
Missed dose:
Administer within 5 days of the scheduled dose.
If more than 5 days have passed, skip the missed dose and continue with the next scheduled dose.
Resume regular once-weekly dosing thereafter.
Important safety note
Retatrutide remains an investigational medication and is not an approved routine weight-loss treatment. The dosing information printed on this pen should not be treated as a verified or medically approved dosing schedule. The conflicting maximum-dose instructions are a particular reason to verify the product and its instructions with a qualified healthcare professional before us